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The development and use of antibiotics has been one of the
most important steps towards controlling infectious diseases in
the 20th century. However, the subsequent appearance and
spread of antibiotic resistance in pathogenic organisms have
made many currently available antibiotics ineffective (160,
169). As a consequence, tuberculosis and other infectious dis-
eases are reemerging, causing a serious public health problem
(32, 38). To successfully fight the increasing numbers of drug-
resistant and multidrug-resistant (MDR) bacteria, extensive
knowledge of the molecular mechanisms underlying microbial
antibiotic resistance is required.
Microorganisms have developed various ways to resist the
toxic effects of antibiotics and other drugs (Fig. 1) (83, 169).
One of these mechanisms involves the production of enzymes
that inactivate antibiotics by hydrolysis or the formation of
inactive derivatives (Fig. 1A) (40). Well-known examples are
b-lactamases (29, 206) and enzymes that phosphorylate, ade-
nylate, or acetylate aminoglycoside antibiotics (234). A second
mechanism of resistance is target alteration (Fig. 1B). Cellular
targets can be altered by mutation or enzymatic modification in
such a way that the affinity of the antibiotic for the target is
reduced (95, 239, 265, 277). A third, more general mechanism
of resistance is the inhibition of drug entry into the cell (Fig.
1C). Due to the low permeability of the outer membrane of
gram-negative bacteria (175, 176) and the exceptionally effi-
cient barrier of the gram-positive mycobacteria (101), drug
diffusion across the cell envelope is reduced. The permeability
of the outer membrane can be further decreased by the loss of
porins (77, 157, 177). These barriers, however, cannot prevent
the drugs from exerting their toxic action once they have en-
tered the cell, and the active efflux of drugs (Fig. 1D) is essen-
tial to ensure significant levels of drug resistance (122, 177).
Some transporters, such as the tetracycline efflux proteins
(209, 237), are dedicated systems which mediate the extrusion
of a given drug or class of drugs. In contrast to these specific
drug transporters, the so-called multidrug transporters can
handle a wide variety of structurally unrelated compounds
(127, 178, 190, 257). On the basis of bioenergetic and structural
criteria, multidrug transporters can be divided into two major
classes (Fig. 2). Secondary multidrug transporters utilize the
transmembrane electrochemical gradient of protons or sodium
ions to drive the extrusion of drugs from the cell. ATP-binding
cassette (ABC)-type multidrug transporters use the free en-
ergy of ATP hydrolysis to pump drugs out of the cell.
Here we present a comprehensive review describing the
currently known multidrug transporters in bacteria. Important
issues addressed are (i) the functional reconstitution of puri-
fied multidrug transporters into proteoliposomes, which allows
detailed molecular characterization of the proteins, (ii) the
transcriptional regulation of genes encoding multidrug efflux
systems, (iii) the structure-function relationships that dictate
drug recognition and transport, (iv) the presence of multiple
drug-binding sites, and (v) the mechanism of transport of both
ATP-driven and secondary multidrug transporters.
SECONDARY MULTIDRUG TRANSPORTERS
Most bacterial multidrug efflux systems known to date are
sensitive to agents that dissipate the proton motive force
(PMF), indicating that they mediate the extrusion of toxic
compounds from the cells in a coupled exchange with protons
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(15, 42, 84, 133, 190). On the basis of size and similarities in the
primary and secondary structure, these secondary multidrug
transporters can be subdivided into distinct families of trans-
port proteins: the major facilitator superfamily (MFS) (146),
the small multidrug resistance (SMR) family (191), the resis-
tance-nodulation-cell division (RND) family (216), and the
multidrug and toxic compound extrusion (MATE) family (28).
These families are not solely associated with multidrug export
but include proteins involved in other PMF-dependent trans-
port processes or other functions.
Major Facilitator Superfamily
The MFS consists of membrane transport proteins which are
found from bacteria to higher eukaryotes and are involved in
the symport, antiport, or uniport of various substrates, such as
sugars, Krebs cycle intermediates, phosphate esters, oligosac-
charides, and antibiotics (146). Hydropathy analysis and align-
ment of conserved motifs of the resistance-conferring drug
efflux proteins revealed that these proteins can be divided into
two separate clusters, with either 12 or 14 transmembrane
segments (TMS) (Fig. 3 and 4) (188). Table 1 summarizes the
multidrug transporters from both the 12-TMS and 14-TMS
clusters found in gram-positive and gram-negative bacteria.
The 12-TMS cluster of multidrug transporters. The Staph-
ylococcus aureus NorA protein was first discovered in a quin-
olone- and methicillin-resistant clinical isolate (251). Sequenc-
ing and characterization of the norA gene revealed that NorA
is a 388-amino-acid membrane protein that confers resistance
to hydrophilic compounds and only low or no resistance to
hydrophobic drugs (271, 278). Studies on the substrate speci-
ficity demonstrated that NorA is a true multidrug transporter,
mediating resistance to a range of structurally dissimilar drugs
(171, 172).
A structural and functional homolog of NorA has been
found in a Bacillus subtilis strain selected with increasing con-
centrations of rhodamine 6G and named Bmr for bacterial
FIG. 1. Resistance mechanisms in bacteria comprise (A) drug inactivation,
(B) target alteration, (C) prevention of drug influx, and (D) active extrusion of
drug from the cell.
FIG. 2. Schematic representation of the two major classes of multidrug transporters. (A) ABC-type multidrug transporters utilize the free energy of ATP hydrolysis
to pump drugs out of the cell. (B) Secondary multidrug transporters mediate the extrusion of structurally unrelated drugs in a coupled exchange with protons or sodium
ions.
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multidrug resistance (170). Ahmed et al. (4) described a sec-
ond multidrug transporter of B. subtilis. This protein, named
Blt, is highly homologous to Bmr and confers resistance to a
similar range of drugs. Despite the similarities between Bmr
and Blt, their expression patterns are different. Under standard
cultivation conditions, Bmr is expressed while the expression of
Blt is undetectable. The differences in regulation of transcrip-
tion and the operon organization suggest that Bmr and Blt
have distinct physiological functions and that the two trans-
porters may be involved in the transport of different natural
substrates (4).
PMF-dependent drug extrusion in Lactococcus lactis was
first observed in strains exposed to increasing stepwise concen-
trations of daunomycin and rhodamine 6G (20). The gene
responsible for this activity, lmrP, encodes an integral mem-
brane protein that shows 19 and 24% homology with the mul-
tidrug transporters Bmr and NorA, respectively (21). Trans-
port studies in whole cells and inside-out membrane vesicles
demonstrated that LmrP mediates the electrogenic export of
lipophilic drugs from the inner leaflet of the membrane to the
aqueous phase (23, 203) (see below).
The Escherichia coli transporter Bcr confers resistance to the
diketopiperazine antibiotic bicyclomycin (18). Vedantam-Gay-
atri et al. (261) revealed that the sulfathiazole resistance de-
terminant sur is identical to bcr, indicating that Bcr is involved
in resistance to structurally unrelated antibiotics. EmrD, an E.
coli homolog of Bcr, is involved in a low-energy shock adaptive
response. Expression of EmrD protects the cell against the
uncouplers CCCP (carbonyl cyanide m-chlorophenylhydra-
zone) and tetrachlorosalicylanilide, but does not affect resis-
tance to bicyclomycin, quinolones, or chloramphenicol, sug-
gesting that EmrD has a fairly narrow substrate spectrum
(167). Another MDR transporter found in E. coli is MdfA (49),
also known as Cmr (179) and CmlA (208), which was initially
described as a membrane-associated efflux pump for chloram-
phenicol. However, detailed analysis of the substrate spectrum
revealed that MdfA confers resistance to a wide range of un-
related neutral and positively charged drugs. Substitutions of
E26 in the first transmembrane segment demonstrated that a
single membrane-embedded negatively charged residue is crit-
ical for the recognition of positively charged drugs by MdfA
(50). Surprisingly, overexpression of MdfA causes decreased
resistance to spectinomycin (19). Thus, the activity of a multi-
drug pump can result in resistance to several toxic compounds
and increased sensitivity to certain others.
The multidrug transporter Cmr of the nonpathogenic organ-
ism Corynebacterium glutamicum significantly increases resis-
tance to several structurally unrelated antibiotics when ex-
pressed in E. coli but does not affect antibiotic resistance when
expressed in C. glutamicum. The inability of Cmr to confer
FIG. 3. Structural model for the 12-TMS multidrug transporters of the MFS. The residues constituting the conserved sequence motifs are shaded.
FIG. 4. Structural model for the 14-TMS multidrug transporters of the MFS. The residues constituting the conserved sequence motifs are shaded.
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resistance in its original host could result from a lower expres-
sion level of Cmr (98).
Mycobacteria cause several diseases, including tuberculosis
and leprosy. The treatment of these infections is often difficult
because mycobacteria are intrinsically resistant to most com-
monly used antibiotics. The Tap multidrug efflux pump in
Mycobacterium fortuitum and Mycobacterium tuberculosis con-
fers resistance to aminoglycosides and tetracycline and makes
it more difficult to control mycobacterial infections (5). The
number of TMS could not be unambiguously determined from
the primary sequence and was estimated to be close to 10.
However, Aı´nsa et al. (5) suggested, on the basis of the ho-
mology between Tap and other multidrug transporters of the
MFS, that Tap is a 12-TMS transporter.
Several studies suggested that a reserpine-sensitive multi-
drug transporter is involved in fluoroquinolone resistance in
Streptococcus pneumoniae (15, 25, 26, 279). Recently, Gill et al.
(63) cloned and characterized the efflux pump PmrA of S.
pneumoniae. Analogous to NorA, Bmr, and LmrP, PmrA is
inhibited by the plant alkaloid reserpine. Expression of PmrA
increases resistance to acriflavine, ethidium, and the fluoro-
quinolones ciprofloxacin and norfloxacin.
The 14-TMS cluster of multidrug transporters. Resistance
to antiseptic and disinfectant compounds, including intercalat-
ing dyes, quarternary ammonium compounds, and diamines, is
widespread among multidrug-resistant strains of Staphylococ-
cus aureus. One of the energy-dependent export mechanisms
responsible for this resistance is encoded by the qacA gene
(248). Hydropathy analysis (213) and topological analysis using
alkaline phosphate and b-galactosidase fusions (192) indicated
that the QacA protein contains 14 TMS. Whereas QacA con-
fers resistance to monovalent and divalent organic cations, the
closely related QacB only confers resistance to monovalent
organic cations (192). It has been speculated that the extensive
use in hospital environments of bacteriostatic divalent cations,
such as chlorhexidine, resulted in the evolution of qacA from
qacB (193).
Sequencing of an E. coli locus for multidrug resistance re-
vealed the presence of two open reading frames, designated
ermA and emrB (135). The emrB gene encodes a 513-amino-
acid protein which is homologous to QacA. ErmA, a 42.7-kDa
membrane fusion protein with a single TMS and a large C-
terminal periplasmic domain, is thought to form a continuous
channel between the inner and outer membrane (126, 135).
EmrAB confers resistance to hydrophobic uncouplers and an-
tibiotics (59, 135). Tanabe et al. (246) characterized the E. coli
emrKY operon. Transcription of emrKY is growth phase depen-
dent and induced by tetracycline. EmrK and EmrY are 50 and
63% identical to EmrA and EmrB, respectively, suggesting a
similar function. However, the involvement of EmrKY in mul-
tidrug efflux remains to be demonstrated.
Bmr3, a third B. subtilis multidrug transporter, shows mod-
erate homology to EmrB (25% identity). Bmr3 confers resis-
tance to the antibiotics puromycin, tosufloxacin, and norfloxa-
cin. Northern hybridization analysis revealed that expression of
Bmr3 is decreased in the late log phase (181).
Shortly after the introduction of fluoroquinolones for the
treatment of tuberculosis, resistant clinical isolates of M. tu-
berculosis were described. From the rapidly growing Mycobac-
terium smegmatis, which was used as a model genetic system for
M. tuberculosis, the lfrA gene, which confers low-level fluoro-
quinolone resistance when present on a multicopy plasmid, was
isolated. LfrA confers resistance to hydrophilic quinolones but
not to the more hydrophobic quinolones (134). Hybridization
analysis showed that LfrA homologs are present in M. tuber-
culosis and Mycobacterium avium (244).
Vibrio cholerae, an important gram-negative enteric patho-
gen, is the causative agent of the severe diarrheal disease
cholera. Colmer et al. (37) identified a multidrug resistance
pump, VceAB, that provides V. cholerae with resistance to
several toxic compounds, including deoxycholate and the anti-
biotics nalidixic acid and chloramphenicol. VcreA and VceB
show significant homology to EmrA and EmrB, respectively.
Small Multidrug Resistance Family
Multidrug transporters of the SMR family (Table 2, Fig. 5),
the smallest secondary drug efflux proteins known, are typically
about 107 amino acid residues in length. Hydropathy analysis
(191), gene fusions with alkaline phosphatase and b-galactosi-
dase (179), a-periodicity analysis (51), cysteine accessibility
scanning (242), and Fourier transform infrared spectroscopy
(11) support a model of a tightly packed four-helix antiparallel
bundle. Due to the small size of the multidrug transporters of
the SMR family, it has been proposed that they may function
as homooligomeric complexes (187, 189).
TABLE 1. MFS multidrug transporters
Multidrug transporter Organism Accession no(s). Reference(s)
12-TMS cluster
Bcr Escherichia coli X63703 18
Blt Bacillus subtilis L32599 4
Bmr Bacillus subtilis M33768 170
Cmr Corynebacterium glutamicum U43535 98
EmrD Escherichia coli P31442 168
LmrP Lactococcus lactis X89779 21
MdfA (Cmr/CmlA) Escherichia coli Y08743, U44900 49, 179
NorA Staphylococcus aureus D90119 278
PmrA Streptococcus pneumoniae AJ007367 63
Tap Mycobacterium fortuitum, Mycobacterium tuberculosis AJ000283 5
14-TMS cluster
Bmr3 Bacillus subtilis D50098 181
EmrB Escherichia coli P27304 135
LfrA Mycobacterium smegmatis U40487 244
QacA Staphylococcus aureus X56628 213
QacB Staphylococcus aureus U22531 191
VceB Vibrio cholerae AF012101 37
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The first gene encoding a multidrug transporter of the SMR
family was detected on both conjugative and nonconjugative
plasmids from clinical isolates of S. aureus and other staphy-
lococci (120, 121, 132). This gene, first described as qacC and
also known as qacD (132) and ebr (221), has been renamed smr
(71). Grinius and Goldberg (72) demonstrated that the puri-
fied and reconstituted Smr protein mediates electrogenic drug/
proton antiport. In staphylococci isolated from the food indus-
try, plasmids pST94 and p2H6 were found. Sequence analysis
of these plasmids revealed two new members of the SMR
family, designated QacG and QacH (84, 85). QacG and QacH
have 69 and 76% identity to Smr, respectively. Both transport-
ers confer resistance to ethidium bromide and quaternary am-
monium compounds.
The E. coli multidrug transporter EmrE (also known as
MvrC) has been identified and cloned on the basis of its ability
to confer resistance to ethidium and methyl viologen (162,
202). Yerushalmi et al. (275) demonstrated that resistance is
caused by PMF-dependent extrusion of drugs. Negative dom-
inance studies indicated that EmrE functions as a homooli-
gomer, probably composed of three monomers (276). Studies
using single cysteine mutants of EmrE showed that none of the
residues in the putative transmembrane helices react with N-
ethyl-maleimide (NEM), a small membrane-permeant sulfhy-
dryl reagent. As the reaction with NEM requires water, the
results imply very tight packing of the protein without a con-
tinuous aqueous domain. Based on these findings, it was pro-
posed that EmrE translocates its substrates through a hydro-
phobic pathway (242).
The antiseptic resistance genes qacE and qacED1 are lo-
cated on an integron, a potentially mobile element. As a con-
sequence, these genes are widely spread among gram-negative
bacteria (108). The qacED1 gene but not the qacE gene was
detected in clinical isolates of gram-positive bacteria (109).
The qacE gene was originally found on the Klebsiella aerogenes
plasmid R751 (187). The qacED1 gene probably represents a
disrupted form of qacE that evolved as a result of the insertion
of a DNA segment near the 39 end of the qacE gene. Ethidium
transport experiments indicated that the mechanism of resis-
tance mediated by QacE is active export driven by the PMF.
Neither QacE nor QacDE1 is inhibited by reserpine, a potent
inhibitor of multidrug transporters such as Bmr, NorA, and
LmrP (187).
The multidrug transporter Mmr of M. tuberculosis confers
resistance to tetraphenyl phosphonium (TPP1), ethidium bro-
mide, erythromycin, acriflavine, safarin O, and pyronin Y (42).
TPP1 accumulation experiments showed that Mmr actively
extrudes TPP1, using the PMF as the driving force. The pres-
ence of mmr-like genes in other Mycobacterium species (M.
simiae, M. gordonae, M. marinum, and M. bovis) was demon-
strated by Southern hybridization (42).
The Bacillus subtilis genome encodes seven SMR-type pro-
teins (194). Surprisingly, six of these proteins are encoded from
gene pairs in three distinct operons, ebrAB, ykkCD, and yvdRS.
Masaoka et al. (154) demonstrated that neither EbrA nor
EbrB is sufficient for conferring drug resistance. However,
coexpression of the two proteins causes an MDR phenotype in
both E. coli and B. subtilis. A similar result was obtained for the
YkkCD pair. Only when both the ykkC and ykkD genes were
expressed together was resistance observed against a broad
range of drugs, including cationic dyes and neutral and anionic
antibiotics (97). In contrast to the SMR-type multidrug trans-
porters, which appear to function as homooligomers, EbrAB
and YkkCD are composed of two dissimilar but homologous
subunits. One member of each pair is short (105 to 106 amino
FIG. 5. Structural model for multidrug transporters of the SMR family. The residues constituting the conserved sequence motifs are shaded.
TABLE 2. SMR multidrug transporters
Multidrug transporter Organism Accession no(s). Reference(s)
EbrA Bacillus subtilis AB029306 154
EbrB Bacillus subtilis AB029306 154
EmrE (MvrC) Escherichia coli Z11877, M62732 162, 202
Mmr Mycobacterium tuberculosis Z83866 42
QacE Gram-negative bacteria X68232 187
QacED1 Gram-negative 1 gram-positive bacteria X68232 187
QacG Staphylococcus spp. Y16944 85
QacH Staphylococcus saprophyticus Y16945 84
Smr (Ebr/QacC/QacD) Staphylococcus aureus X15574, M37888, M37889, M33479 71, 132, 221
YkkC Bacillus subtilis P49856 97
YkkD Bacillus subtilis AJ002571 97
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acids), while the other is longer (111 to 117 amino acids). This
difference is due to a C-terminal hydrophilic extension (97).
The tehA gene of E. coli, which was initially identified as part
of an operon associated with resistance to potassium tellurite,
encodes a 36-kDa protein with 10 TMS (247). Surprisingly, a
region of TehA which includes TMS 2 through 5 was found to
be homologous to members of the SMR family (250). Expres-
sion of TehA increased the resistance to monovalent cations,
such as tetraphenylarsonium and ethidium bromide, but de-
creased the resistance to the divalent cations dequalinium and
methyl viologen (250). Thus, like MdfA of E. coli, TehA con-
fers resistance to one group of toxic compounds and hypersen-
sitivity to another group. Since deletion of the C-terminal re-
gion of TehA (TMS 8 to 10) did not decrease transport
significantly, TMS 2 to 5 may be primarily responsible for the
activity of TehA (250). Although TehA contains only one of
the three SMR signature sequences (191) and is larger than the
reported SMR-type multidrug transporters, it may represent a
distantly related member of the SMR family.
Resistance-Nodulation-Cell Division Family
Multidrug transporters belonging to the RND family (Table
3) interact with a membrane fusion protein (MFP) and an
outer membrane protein to allow drug transport across both
the inner and outer membrane of gram-negative bacteria. The
secondary structure of RND-type efflux proteins (Fig. 6) was
proposed to consists of 12 TMS, with two large loops between
TMS 1 and 2 and TMS 7 and 8 (190, 216). Membrane topology
analysis of the Pseudomonas aeruginosa RND protein MexB
recently verified this model (75). The MFP proteins, which
contain a single N-terminal TMS and a large C-terminal
periplasmic domain, are thought to induce fusion of the inner
and outer membrane (45, 216) or form a channel-like structure
that spans the periplasmic space (281).
The acrA locus of E. coli has long been known to be involved
in resistance to basic dyes, detergents, and antibiotics (166,
167). Characterization of this locus revealed the presence of
two genes, acrA and acrB (formerly acrE), which are located
within a single operon (141). AcrA is a highly asymmetric
protein that belongs to the MFP family, while AcrB is a mem-
ber of the RND family (45, 281). Insertion mutations showed
that both AcrA and AcrB are required for drug resistance
(143). A study by Fralick (58) suggested that the outer mem-
brane protein TolC is the third component of the AcrAB efflux
system. Recently, the 2.1-Å crystal structure of TolC has been
determined (118). Three TolC promoters assemble to form a
continuous, solvent-accessible “tunnel” that spans the outer
membrane and periplasmic space. This tunnel may transiently
open up upon the interaction with an energized inner mem-
brane transporter and establish a conduit between the cytosol
and the external environment. E. coli contains two AcrAB
homologs, AcrEF (formerly known as EnvCD [110]) and
YhiUV (formerly called OrfAB), as well as an AcrB homolog,
AcrD, which is not associated with a gene for an MFP (142).
Inactivation of AcrEF decreased the resistance to a broad
range of drugs, including dyes, detergents, and various classes
of clinically important antibiotics, indicating that AcrEF func-
tions as a multidrug transporter (141). Mutations in the yhiUV
genes result in drug hypersusceptibility, suggesting that YhiUV
also plays a role in antibiotic resistance (142, 143). Direct
multidrug transport, however, has not yet been demonstrated.
P. aeruginosa is a clinically important opportunistic pathogen
characterized by relatively high intrinsic resistance to a variety
of antimicrobial agents. This property is now recognized to
result from the synergy between low outer membrane perme-
ability and at least four RND efflux systems. The mexAB-oprM
operon was first thought to play a role in the export of the
siderophore pyoverdine (198). Further characterization of the
operon, however, showed that overexpression of MexAB-
OprM increased the resistance of P. aeruginosa to various
antibiotics (199). A direct assay of drug accumulation showed
that MexAB-OprM indeed pumps out various antibacterial
agents in an energy-dependent fashion (129). MexA and MexB
are members of the MFP and RND families, respectively. The
third gene of the operon was originally identified as oprK, but
Gotoh et al. (64) demonstrated that the outer membrane com-
ponent of this efflux system is OprM rather than OprK. Results
obtained by Evans et al. (52) suggested that the quorum-sens-
ing-related homoserine lactone PAI-1 is a substrate for
MexAB-OprM and that exclusion of PAI-1 limits the produc-
tion of virulence factors, such as the blue-green pigment pyo-
cyanin. Examination of P. aeruginosa strains showing widely
different levels of intrinsic resistance suggested the presence of
more than one endogenous multidrug efflux system (128). In-
deed, Poole and coworkers (200) identified a second efflux
operon in P. aeruginosa, designated MexCD-OprJ. The third
antibiotic efflux system of P. aeruginosa is composed of the
MFP MexE, the RND protein MexF, and the outer membrane
protein OprN (115). Similar to MexAB-OprM, MexEF-OprN
expression correlates inversely with the production of the vir-
ulence factor pyocyanin (115). In contrast to MexAB-OprM,
MexCD-OprJ and MexEF-OprN do not confer resistance to
b-lactam antibiotics (65, 115). Subunit swapping experiments
demonstrated that the inner membrane efflux components of
the MexAB-OprM transporter are responsible for the b-lac-
tam specificity of the multidrug efflux pumps in P. aeruginosa
(66, 155, 240). Recently, two new genes mediating resistance to
quinolones, aminoglycosides, and macrolide antibiotics were
cloned from the chromosome of P. aeruginosa (6, 158). These
genes, designated mexX and mexY, show significant similarity
to mexAB, mexCD, and mexEF. No open reading frame corre-
sponding to an outer membrane protein was found down-
stream of mexXY. Mine et al. (158) demonstrated that TolC or
OprM is required for MexXY activity in E. coli. It has been
reported that OprM contributes to antibiotic resistance in P.
aeruginosa independent of MexAB (283). The substrate spec-
ificity of this OprM-dependent and MexAB-independent sys-
tem corresponds to that of the MexXY system, suggesting that
OprM functions as the outer membrane protein of the MexXY
drug efflux pump in P. aeruginosa (158).
The resistance of Neisseria gonorrhoeae to hydrophobic
agents, including detergent-like fatty acids and bile salts, is
conferred by the MtrRCDE efflux system. The mtrRCDE re-
gion of the gonococcal chromosome contains a transcriptional
regulator gene (mtrR) and three tandemly linked genes (mtrC,





AmrB Burkholderia pseudomallei AF072887 161
AcrB Escherichia coli U00734 141
AcrF (EnvD) Escherichia coli X57948 110
HI0895 Haemophilus influenzae L42023 57
MexB Pseudomonas aeruginosa L11616 198
MexD Pseudomonas aeruginosa U57969 200
MexF Pseudomonas aeruginosa X99514 115
MexY Pseudomonas aeruginosa AB015853 158
MtrD Neisseria gonorrhoeae U60099 81
YhiV Escherichia coli U00039 143
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mtrD, and mtrE), encoding proteins of the MFP, RND, and
outer membrane protein families, respectively (80). Insertional
inactivation of either the mtrC (80) or mtrE (41) gene resulted
in a significant decrease in resistance to erythromycin, penicil-
lin, Triton X-100, and fatty acids, suggesting that both proteins
are required in the efflux process.
Genome sequencing of Haemophilus influenzae has identi-
fied a three-gene cluster, consisting of HI0893, HI0894, and
HI0895, which is homologous to the acrRAB cluster of E. coli
(57). Disruption of either HI0894 (an acrA homolog) or
HI0895 (an acrB homolog) caused hypersusceptibility to eryth-
romycin, rifampin, novobiocin, sodium dodecyl sulfate, and
cationic dyes. Erythromycin accumulation experiments indi-
cated that the HI0894 and HI0895 proteins contribute to the
resistance of H. influenzae through PMF-dependent drug efflux
(220).
Burkholderia pseudomallei, a motile gram-negative rod, is
the causative agent of melioidosis. Successful treatment of
melioidosis patients is difficult because B. pseudomallei is in-
trinsically resistant to a variety of antibiotics, including b-lac-
tams, aminoglycosides, and macrolides. Recently, the amrAB-
OprA operon was identified, which encodes a multidrug efflux
system in B. pseudomallei which confers resistance to both
aminoglycoside and macrolide antibiotics. AmrA and AmrB
show strong homology to MexC and MexB, respectively, of P.
aeruginosa (161).
Multidrug and Toxic Compound Extrusion Family
Norfloxacin accumulation experiments revealed that Vibrio
parahaemolyticus contains an energy-dependent efflux system,
designated NorM (163). NorM and its E. coli homolog YdhE
mediate resistance to dyes, hydrophilic fluoroquinolones, and
aminoglycosides. NorM contains 12 putative TMS, and on this
basis it has been suggested to be a member of the MFS (163).
NorM and YdhE, however, do not have sequence similarity
with any members of the MFS and do not exhibit any of the
signature sequences (see below). Brown et al. (28) found that
FIG. 6. Structural model for multidrug transporters of the RND family. The residues constituting the conserved sequence motifs are shaded.
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NorM and YdhE are members of a previously unidentified
family which contains more than 30 proteins, termed the mul-
tidrug and toxic compound extrusion (MATE) family. Phylo-
genetic analysis of the MATE family revealed the presence of
three distinct clusters, of which the first includes NorM, YdhE,
and hypothetical multidrug efflux proteins from H. influenzae
and B. subtilis (28).
Electrogenic Drug/Proton Antiport
Drug transport by multidrug transporters of the MFS, SMR,
RND, and MATE families is driven by the transmembrane
electrochemical gradient of protons or possibly sodium ions.
The PMF is composed of a chemical proton gradient (DpH,
inside alkaline) and an electrical potential (DC, inside nega-
tive). The ionophores nigericin and valinomycin, which can
selectively dissipate the DpH and DC, respectively, are valu-
able tools for the study of the energetics of secondary multi-
drug transporters. Ng et al. (174) demonstrated that NorA-
mediated norfloxacin uptake in inside-out membrane vesicles
was completely abolished by nigericin. In contrast, addition of
valinomycin resulted in a slight increase in the uptake of nor-
floxacin. These results indicate that the DpH is the major
driving force for NorA. Grinius et al. (73) reported that NorA-
mediated drug transport in proteoliposomes is an electrogenic
drug/proton antiport process. Transport experiments in the
presence of valinomycin and/or nigericin showed that both the
DpH and the DC are driving forces of LmrP-mediated trans-
port of trimethyl ammonium-diphenyl hexatriene (TMA-
DPH) (22) and Hoechst 33342 (203), consistent with an elec-
trogenic exchange of one lipophilic cation for two or more
protons. Mitchell et al. (159) investigated which component of
the PMF is involved in energizing QacA-mediated drug efflux.
It was found that both the DpH and the DC drive the electro-
genic transport of monovalent and divalent cations by QacA.
The involvement of both components of the PMF as the driv-
ing force in Smr-mediated drug transport was demonstrated by
studies using purified Smr reconstituted into proteoliposomes.
A DC (positive inside) superimposed on DpH (acidic inside)
resulted in additional ethidium uptake via Smr (72). An elec-
trogenic drug/proton antiport reaction by Smr was further sup-
ported by the observation that Smr increased the resistance of
E. coli cells to ethidium in alkaline medium, when the PMF
predominantly consists of a DC (72). The electrogenic drug/
nH1 (n $ 2) antiport mechanism observed for LmrP, NorA,
QacA, and Smr appears to be a general feature of multidrug
transporters of the MFS and SMR families and may also be
valid for the RND- and MATE-type multidrug transporters.
The substrates used in the studies on the energetics of second-
ary multidrug transporters are monovalent cations. However,
several multidrug transporters, such as QacA, MdfA, and
YkkCD, also mediate resistance to divalent cations, neutral
drugs, and anionic compounds. An analysis of the relative
contribution of the DC and the DpH to the driving force for
transport of these cations can provide further insight into the
drug/proton ratio of the export process.
Conserved Sequences in Secondary Multidrug Transporters
Multiple-sequence analysis of transporters within the vari-
ous clusters of solute and drug transporters of the MFS re-
vealed a substantially larger sequence similarity in the N-ter-
minal halves of these proteins than in their C-terminal halves
(70, 146, 188, 213). It has been hypothesized that the N-termi-
nal domain is involved in proton translocation, while the C-
terminal domain of the transporters is primarily involved in
determining the substrate specificity (70, 213). On the other
hand, the significant sequence similarity observed between the
N- and C-terminal halves of transporters of the MFS suggests
that they have evolved from a duplication of a common ances-
tor with six TMS (122, 145, 215, 274). The 14-TMS cluster of
the MFS may have evolved via a similar gene duplication event
and the acquisition of two additional TMS (70, 188, 217). The
homology between the first and second halves of RND proteins
suggests that these proteins also may have arisen via an intra-
genic duplication event during evolution (75, 216).
The multiple alignments of amino acid sequences further
revealed a number of strongly conserved amino acid sequence
motifs (Table 4 and Fig. 3, 4, 5, and 6) throughout the multi-
drug transporters of the MFS, SMR, and RND families (188,
190, 191, 213, 216). The conservation of these motifs suggests
that they play an important structural or functional role in the
transporters. Motif A in the cytoplasmic loop between TMS 2
and 3 in transporters of the MFS, which is predicted to contain
a b-turn structure, may be involved in the reversible confor-
mational change required for the opening and closing of a
transport channel (102, 188, 272, 273). The absolute conserva-
tion of the basic arginine residue suggests that motif B in TMS
4 of MFS transporters may be involved in proton transfer
(188). Interestingly, motif C in TMS 5 is found in multidrug
transporters and specific drug efflux pumps, but not in sym-
porters of the MFS. This suggests that motif C dictates the
direction of transport (70, 188). The GP dipeptide of this motif
causes a bend in helix 5, and the repeating pattern of glycine
residues forms a pocket devoid of side chains. These structures
may determine the orientation of the unoccupied substrate-
binding site(s) and, consequently, the direction of transport
(261). The C-terminal motifs F and G represent partial dupli-
cations of motif C and may have a similar function. Site-
directed mutagenesis studies can provide valuable information
on the structure and mechanism of multidrug transporters of
the MFS, RND, and SMR families. The conserved motifs may
be directly involved in drug or proton translocation. The
charged residue in motif B (Arg) and in motif D1 (Asp) in
members of the MFS, in motif A (Glu) in SMR-type multidrug
transporters, and in motif C (two Arg) in drug efflux systems of
the RND family are predicted to be located in TMS. The
presence of positively or negatively charged amino acid resi-
dues in the membrane is energetically unfavorable, suggesting
that these motifs play a functional role in the binding and
transport of charged drugs and/or translocation of protons.
Alternatively, they may play a structural role in the interaction
between the transporters of the RND family (motif A) and
proteins of the MFP family, or in the formation of homo- and
heterooligomers of SMR-type multidrug transporters. The
conserved sequences are characteristic of proteins of the MFS,
SMR, and RND families and can be used to identify new
members of these families in bacterial genomes.
Re´sume´
The secondary multidrug transporters identified in bacteria
(Tables 1 to 3) belong to one of four distinct families of pro-
teins, MFS, SMR, RND, and MATE. Whereas multidrug
transporters of the MFS and SMR families have been found in
both gram-positive and gram-negative bacteria, RND- and
MATE-type multidrug transporters have so far only been iden-
tified in gram-negative organisms. Table 5 indicates that bac-
teria can contain several multidrug transporters from different
families. The presence of a variety of multidrug transporters
with an overlapping substrate spectrum would seem redun-
dant. However, the availability of an array of multidrug trans-
porters, which are controlled by both global and specific reg-
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ulatory proteins, enables the bacterium to fine tune the
response to different environmental signals.
The most striking difference between multidrug transporters
of the SMR family and drug efflux systems from the other
families is their size. Whereas members of the MFS, RND, and
MATE families consist of 12 or 14 TMS, SMR-type multidrug
transporters only contain 4 TMS. These small multidrug efflux
pumps are thought to function as homooligomers, presumably
composed of three monomers. However, two new SMR-type
multidrug transporters were recently identified in B. subtilis
which require two homologous but dissimilar subunits for drug
efflux. This observation raises the question of what molecular
determinants dictate whether an SMR transporter functions as
a homo- or heterooligomer.
Secondary multidrug transporters extrude drugs in exchange
with protons (or sodium ions). Both components of the PMF
can drive the extrusion of drugs by multidrug transporters from
the MFS, SMR, and RND families, indicating that an electro-
genic antiport mechanism is a general feature of secondary
multidrug transporters.
Multiple sequence alignments of transporters within one
family revealed the presence of three or more conserved motifs
in multidrug transporters of the MFS, SMR, and RND families
(Table 4). Hydropathy analysis, the recognition of family-spe-
cific conserved motifs, and the availability of the complete
genomic sequences of 28 bacteria and 8 archaea (http://www
.tigr.org/tdb/mdb) enable the identification of putative multi-
drug transporters. However, as multidrug transporters are fre-
quently more homologous to substrate-specific transporters
than to other multidrug transporters, the activity of newly
identified proteins needs to be characterized.
ATP-DEPENDENT MULTIDRUG TRANSPORTERS
Although most bacterial multidrug drug transporters utilize
the PMF (or sodium) for the extrusion of cytotoxic com-
pounds, some drug efflux systems are driven by the free energy
of ATP hydrolysis (Fig. 7). All ATP-dependent drug efflux
proteins known to date are members of the ABC superfamily
(87), also referred to as traffic ATPases (8). In general, ABC
transporters require four distinct domains: two highly hydro-
phobic membrane domains, which usually consist of six puta-
tive transmembrane a-helices each, and two hydrophilic nucle-
otide-binding domains (NBDs), containing the Walker A and
B motifs (263) and the ABC signature (96). The individual
domains can be expressed as separate proteins or may be fused
into multidomain polypeptides in a variety of ways (55, 87, 96).
Most bacterial ABC drug transporters mediate the export of
specific antibiotics (17, 55, 76, 130, 183, 197, 210, 212). The first
true bacterial ABC multidrug transporter was found in Lacto-
coccus lactis (20). The gene encoding this transporter, desig-
nated lmrA, encodes a 590-amino-acid membrane protein with
an N-terminal hydrophobic domain with six putative trans-
membrane helices and a C-terminal hydrophilic domain, con-
TABLE 4. Consensus sequences of conserved motifs in transporters of the MFS, SMR, and RND families
Motif Consensus sequencea Location
MFS, both 12- and
14-TMS cluster
A G x L a D r x G r k x x (x) l Loop between
TMS 2 and 3
B l x x x R x x q G x g a a TMS 4
C g x x x G P x x G G x l End of TMS 5
MFS, 12-TMS
cluster
D2 l g x x x x x P v x P End of TMS 1
G G x x x G P L End of TMS 11
MFS, 14-TMS
cluster
D1 l D x T v x n v A l P End of TMS 1
E D x x G x x L TMS 7
F l g x x x G x a v x g x l TMS 13
H W x w x F l l N v P i g TMS 6
SMR family
A W i x l v i A i l l E V TMS 1
B K x s e G F t r l x P S Loop between
TMS 1 and 2
C P v G t A Y A v W t G l G Start of TMS 3
RND family
A G x s x v T v x F x x g t D x x x A q v q V q n k L q x A x p x L P x x V q x q g x x v x k Loop between
TMS 1 and 2
B a l v l s a V F l P m a f f g G x t G x i y r q f s i T x v s A m a l S v x v a l t l t P A l c A TMS 6
C x x x G k x l x e A x x x a a x x R L R P l L M T s L a f i l G v l P l a i a t G x A G a TMS 11
D S i N t l T l f g l v l a i G L l v D D A l V v V E N v e R v l a e TMS 4
a The motifs were identified by alignment of amino acid sequences (190, 191). The consensus sequences of the motifs are displayed as follows: x, any amino acid;
capital letters, amino acid occurs in .70% of the examined sequences; lowercase letters, amino acid occurs in .40%; (x), amino acid not always present.
TABLE 5. Number of sequenced and functionally characterized







Bacillus subtilis 2 1 2 0 0
Escherichia coli 3 1 1 3 1
Staphylococcus aureus 1 2 3 0 0
Mycobacterium tuberculosis 1 1 1 0 0
Pseudomonas aeruginosa 0 0 0 4 0
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taining the ATP-binding cassette (256). LmrA is homologous
to each of the two halves of the human multidrug transporter
P-glycoprotein (256), suggesting that LmrA is functional as a
homodimer. This suggestion was confirmed by studies on co-
valently linked dimers composed of wild-type LmrA units (des-
ignated KK), mutant LmrA units containing an inactivated
NBD (designated MM), and combinations of wild-type and
mutant units (designated KM and MK) (258). The ethidium
transport activity and substrate-stimulated ATPase activity of
the KK dimeric form of LmrA was comparable to that of
wild-type LmrA. However, the KM, MK, and MM mutant
forms of dimeric LmrA had lost all LmrA-associated ATPase
activity and the ability to transport ethidium from the cell.
These results are supported by reconstitution experiments
which demonstrate the negative dominance of M units over K
units in proteoliposomes and suggest that homodimeric LmrA
is the minimal functional unit. Hence, functional crosstalk be-
tween two LmrA monomers is essential for activity (258).
When expressed in human lung fibroblast cells, LmrA is
targeted to the membrane and confers multidrug resistance on
these human cells (257). The pharmacological characteristics
of LmrA and the human multidrug transporter P-glycoprotein
(67) and the affinities of both proteins for vinblastine and
Mg21-ATP are very similar. Blockers of P-glycoprotein also
inhibited LmrA-mediated resistance. These results demon-
strate that LmrA and the human multidrug transporter P-
glycoprotein are functionally interchangeable, indicating that
this type of multidrug transporter is conserved from bacteria to
humans (258).
Kinetic analysis of vinblastine dissociation from LmrA and
characterization of transport of Hoechst 33342 or vinblastine
in the presence of low concentrations of a second substrate
revealed that LmrA contains at least two allosterically linked
drug-binding sites with overlapping substrate specificities (see
below) (257, 258). Purified LmrA reconstituted in proteolipo-
somes mediates ATP-dependent transport of Hoechst 33342
(147). Certain ABC transporters, including the LmrA homolog
MsbA of E. coli (285), are able to translocate lipids. The
specificity of reconstituted LmrA for C6-NBD-labeled phos-
phatidylethanolamine and phosphatidylcholine was investi-
gated. Interestingly, LmrA catalyzes the transport of C6-NBD-
labeled phosphatidylethanolamine but not of C6-NBD-labeled
phosphatidylcholine. These results indicate that LmrA exhibits
specificity for phospholipid headgroups and that LmrA may be
involved in the translocation of specific lipid or lipid-linked
precursors in L. lactis (147).
Hop-resistant lactobacilli can cause serious spoilage of beer.
Sami et al. (218, 219) demonstrated that plasmid pRH45 of
Lactobacillus brevis is involved in the high resistance to hop
compounds (iso-a-acids). pRH45 contains the horA gene,
FIG. 7. Structural model for multidrug transporters of the ABC superfamily. Shown is the multidrug transporter LmrA, with six transmembrane helices and an
NBD, containing the Walker A and B motifs and the ABC signature sequence. In view of the general four-domain organization, it may function as a homodimer. The
Walker A and B motifs and the ABC signature sequence are shaded.
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which encodes a protein of the ABC superfamily. HorA is a
structural homolog of LmrA, containing six putative TMS and
a C-terminal ATP-binding domain. In addition to conferring
hop resistance, HorA confers resistance to the structurally
unrelated drugs novobiocin and ethidium (219). HorA has
been heterologously expressed in Lactococcus lactis, purified,
and functionally reconstituted in proteoliposomes. HorA-me-
diated Hoechst 33342 transport in proteoliposomes is inhibited
by hop compounds (K. Sakamoto et al., submitted for publi-
cation).
Kaidoh et al. (105) described an ATP-dependent drug efflux
system in the archaeon Haloferax volcanii. This efflux system
mediates the transport of doxorubicin, vinblastine, vincristine,
ethidium, and monensin. Expression of the transporter is in-
duced in media containing a large excess of essential amino
acids, glucose, or fructose. These observations suggest that this
efflux system plays a role in the active extrusion of cytotoxic
compounds or toxic metabolites generated in the cell. The
gene encoding this ABC-type multidrug transporters remains
to be cloned and sequenced (105). Genome sequencing re-
vealed the presence of putative LmrA homologs in E. coli, B.
subtilis, and the pathogens Helicobacter pylori, Mycobacterium
genitalium, H. influenzae, and S. aureus (259). Functional char-
acterization of these proteins is required to demonstrate their
involvement in the ATP-dependent transport of structurally
unrelated drugs.
Mutant analysis and photoaffinity labeling experiments have
been used to identify essential residues and putative substrate-
binding sites in the human multidrug transporter P-glycopro-
tein. The results demonstrated that, although some mutations
leading to changes in specificity are located in other regions of
the protein, TMS 5, 6, 11, and 12 and the loop between TMS
2 and 3 and TMS 11 and 12 are most important in drug binding
and/or transport (39, 43, 68, 69, 82, 106, 137, 139, 164, 282).
Interestingly, sequence conservation between the lactococcal
multidrug transporter LmrA and P-glycoprotein includes parts
of TMS 5 and 6 and the loop between TMS 2 and 3 (256),
indicating that these particular regions may be important for
substrate binding in both human and bacterial ABC-type mul-
tidrug transporters.
REGULATION
Several studies demonstrated that the expression levels of
multidrug transporters such as Bmr, NorA, QacA, and P-gly-
coprotein can be enhanced by the addition of structurally di-
verse compounds which are exported by these pumps (3, 74,
104, 107). These observations indicate that the expression of
multidrug transporters is controlled by regulatory proteins
which, like the transporters, are capable of recognizing struc-
turally diverse compounds. The activator and repressor pro-
teins involved in the transcriptional regulation of multidrug
transporter genes are summarized in Table 6.
The best-studied regulator of multidrug transport is BmrR,
the transcriptional activator of the B. subtilis multidrug trans-
porter Bmr. BmrR, which is encoded by a gene immediately
downstream of bmr, belongs to the MerR family of regulators
and has strong homology with other members of the family
only in the N-terminal helix-turn-helix DNA-binding domain.
Binding of one rhodamine 6G molecule to a dimer of BmrR
increases the affinity of BmrR for the bmr promoter, resulting
in enhanced transcription of the bmr gene (3). The individually
expressed C-terminal region of BmrR forms dimers and binds
a broad range of drugs with the same affinity as full-length
BmrR (148, 150). High-resolution crystal structures of the
BmrR C-terminal region and its complex with TPP1 revealed
drug-induced unfolding and relocation of an a-helix, which
exposes an internal drug-binding pocket. Residue Glu-134,
which is completely buried in the unliganded structure, is the
key to cation selectivity, while a number of nonpolar and aro-
matic side chains impose specific requirements on the size and
shape of the substrate (284). The transcription of the blt gene
is regulated by another member of the MerR family, BltR. The
C-terminal domains of BmrR and BltR have no sequence
similarity, which is consistent with the observation that Bmr
and Blt are expressed in response to different inducers. This
difference in inducer specificity may explain why Bmr and not
Blt is normally expressed in wild-type B. subtilis (4).
The expression of the S. aureus multidrug efflux gene qacA is
regulated by the divergently transcribed repressor protein
QacR. QacR binds specifically to the qacA promoter, prevent-
ing transcription of the gene. Substrates of QacA, such as
ethidium and rhodamine 6G, interact with QacR directly and
inhibit the binding of QacR to the qacA promoter, resulting in
derepression of qacA expression (74).
The EmrAB multidrug pump of E. coli is induced in the
presence of CCCP, the weak acid salicylate, and a number of
other structurally unrelated drugs. The derepression is con-
trolled by the EmrR, a MarR type of repressor protein (136).
EmrR was found to bind putative substrates of the EmrAB
pump, such as 2,4-dinitrophenol, CCCP, and carbonyl cyanide
p-(trifluoro-methoxy)-phenylhydrazone (FCCP), with micro-
molar affinity. Equilibrium dialysis experiments suggested one
bound ligand per EmrR dimer (27).
Analysis of the sequence upstream of the mtrCDE multidrug
efflux system of N. gonorrhoeae revealed the presence of the
divergently transcribed repressor gene mtrR. MtrR binds to the
13-bp inverted repeat sequence between the mtrR and mtrC
promoters, thereby inhibiting expression of the mtrRCDE gene
complex (80, 185). Studies by Hagman and Shafer (79), how-
ever, showed that the MtrCDE efflux system is subject to both
MtrR-dependent and MtrR-independent regulation. Recently,
the transcriptional activator MtrA was shown to be involved in
the modulation of mtrCDE gene expression (214).
The transcription of the acrAB operon in E. coli is regulated
by the repressor AcrR (144). Gel mobility shift assays and lacZ
transcriptional fusions suggested that the general-stress-enhanced
transcription of acrAB (144) is primarily mediated by global reg-
ulatory pathways such as the mar regulon (see below) and that
a major function of AcrR is that of a specific secondary mod-
ulator, which fine tunes the level of acrAB transcription (144).
TABLE 6. Reported transcriptional regulators that control the
expression of multidrug transporters in bacteria
Multidrug
transporter(s) Regulator Type Reference
Blt BltR Activator 4
Blt, Bmr Mta Global activator 16
Bmr BmrR Activator 3
EmrB EmrR Repressor 136
QacA QacR Repressor 74
AcrB MarA Global activator 182
AcrB AcrR Repressor 144
AmrB AmrR Repressor 161
MexB MexR Repressor 201
MexD NfxB Repressor 200
MexF MexT Activator 116
MexZ MexX Repressor 6
MtrD MtrA Activator 214
MtrD MtrR Repressor 185
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The transcriptional repressor AmrR of Burkholderia
pseudomallei shows strong similarity to the regulator MtrR.
The expression of the AmrAB-OprA efflux system was not
affected by the substrate streptomycin or by stress conditions
(4% ethanol or 0.5% NaCl), and further studies are required
to identify the inducers of this system (161).
The expression of the P. aeruginosa multidrug transporter
MexAB-OprM is regulated by MexR, a MarR-type regulator
(53, 201). The transcriptional repressor NfxB regulates a sec-
ond MDR in P. aeruginosa, MexCD-OprJ, as well as its own
expression (200). The mexEF-oprN efflux operon differs from
the other P. aeruginosa efflux systems in that it is positively
regulated by MexT, a protein belonging to the LysR family of
transcriptional activators (115, 116). A third MDR in P. aerugi-
nosa, MexXY, may be regulated by MexZ, which is homolo-
gous to the repressor proteins MtrR and AmrR (6).
In addition to the specific regulatory mechanisms that affect
the expression of single multidrug transporters, induction of
multidrug efflux systems can also result from global regulatory
mechanisms. Multiple-antibiotic resistance (Mar) mutants of
E. coli express elevated levels of resistance to a wide range of
antibiotics. The alleles that affect the Mar phenotype are lo-
cated in the marRAB operon (34). Expression of this operon is
normally repressed by the transcriptional repressor MarR (9,
225) but can be derepressed by various compounds, such as
tetracycline, chloramphenicol, and salicylates (35, 78). The
marA gene encodes an AraC-type activator that is structurally
and functionally similar to two other global regulators of E.
coli, SoxS and Rob (60, 235, 270). The MarA, SoxS, and Rob
proteins are transcriptional activators of at least a dozen pro-
moters, the mar and soxRS regulons, that confer resistance to
a variety of antibiotics and superoxide-generating agents (10,
62, 99, 100, 226). The observed resistance is partly due to
increased micF transcription and the consequent decrease in
expression of the outer membrane porin OmpF (33, 60). The
RND-type multidrug transporter AcrAB-TolC plays a major
role in the antibiotic and organic solvent resistance induced by
MarA, SoxS, or Rob (182, 266). The mar operon is widespread
among enteric bacteria, including the genera Salmonella, Shi-
gella, Klebsiella, Citrobacter, Hafnia, and Enterobacter (36). Ex-
pression of E. coli MarA in Mycobacterium smegmatis resulted
in increased resistance to multiple antimicrobial agents, sug-
gesting that MarA functions in M. smegmatis and that a mar-
like regulatory system exists in mycobacteria (156). Recently,
Baranova et al. (16) identified a global MerR-type regulator in
B. subtilis, termed Mta. The individually expressed N-terminal
DNA-binding domain of Mta mimics the inducer-bound form
and interacts directly with the promoters of bmr and blt,
thereby inducing transcription of these genes. Additionally,
this domain stimulates the expression of the mta gene and at
least one more gene, ydfK, which encodes a hypothetical mem-
brane protein (16).
RECONSTITUTION
Multidrug transporters have predominantly been studied in
whole cells and membrane vesicles, in which other proteins and
cellular components or processes may complicate the interpre-
tation of the data. In order to elucidate the structure, function,
and mechanism of multidrug transporters at the molecular
level, methods have been developed for overexpression, puri-
fication, and functional reconstitution into liposomes (72, 73,
147, 203, 227, 275, 280). Although the overexpression of mem-
brane proteins is often deleterious for the cells (48, 119, 203,
243), drug transporters could be overexpressed up to 5 to 30%
of total membrane protein using homologous expression sys-
tems and inducible promoters, such as the T7 polymerase pro-
moter (275), the lac promoter (236), and the nisA promoter
(147, 203). The first step in the purification of membrane
proteins involves extraction of the protein from the membrane.
The E. coli multidrug transporter EmrE can be quantitatively
and functionally extracted with a mixture of organic solvents,
such as chloroform-methanol (275). However, solubilization of
most other membrane proteins requires the use of detergents
(115). The choice of detergent is crucial, since some detergents
can irreversibly inactivate the protein (227; J. Knol, R. H. E.
Friesen, and B. Poolman, submitted for publication). In addi-
tion, detergents are potential substrates for multidrug efflux
proteins and can affect the transport activity (46, 203, 268).
Retention of detergent during the reconstitution procedure is
a serious problem which further restricts the choice of deter-
gent for the solubilization and reconstitution of multidrug
transporters (115). Affinity chromatography, a highly specific
and efficient technique, allows the purification of several mul-
tidrug transporters to a high degree of purity (.90%) in a
single step (72, 147, 203, 227, 280). After reconstitution in
liposomes, Smr, P-glycoprotein, EmrE, NorA, LmrA, LmrP,
AcrB, and HorA mediated the transport of multiple drugs in
response to the imposition of an artificial proton gradient or
the addition of ATP (72, 73, 147, 203, 227, 275, 280; K. Saka-
moto, H. W. van Veen, and W. N. Konings, unpublished data).
Taken together, these results demonstrate that multidrug
transporters of the MFS, SMR, RND, and ABC families are
capable of mediating drug transport independent of accessory
proteins or cytosolic components.
SUBSTRATE BINDING
Both secondary and ATP-dependent multidrug transporters
extrude a wide variety of toxic compounds. Although the sub-
strates have very different structures, they share physical char-
acteristics, such as high hydrophobicity, an amphiphilic nature,
and a positive or neutral charge. In the absence of three-
dimensional structural information, the identification of struc-
ture-function relationships in multidrug transporters has relied
on amino acid sequence alignments and site-directed mutagen-
esis. The localization of a charged residue in the membrane-
embedded part of the protein is normally considered energet-
ically unfavorable, yet many multidrug transporters of the MFS
and SMR families, such as MdfA, QacA, EmrE, and Smr,
contain an acidic amino acid residue in the middle of TMS 1
(50). Furthermore, Guan et al. (75) identified three highly
conserved negatively charged amino acid residues in trans-
membrane domains of efflux proteins of the RND family. Since
the majority of the MDR substrates are positively charged, the
negative charge of an intramembranous acidic residue may be
involved in substrate binding. The role of the conserved Glu in
TMS 1 of Smr has been investigated using site-directed mu-
tagenesis. Even conservative substitutions, such as the replace-
ment of Glu with Asp, effectively abolished the activity of the
efflux system, indicating that this residue may be directly in-
volved in the multidrug efflux process, potentially in substrate
binding and/or the exchange of drug molecules for protons
(72). Edgar and Bibi (50) demonstrated that a single mem-
brane-embedded negative charge is critical for the recognition
of positively charged drugs by the multidrug transporter MdfA
of E. coli but not for transport activity. Replacement of the Glu
residue in TMS 1 of EmrE abolished binding activity, but
replacement with a negatively charged Asp created a mutant
protein that retained its ability to bind substrate (165).
Whereas QacA transports both monovalent and divalent cat-
ions, the closely related multidrug transporter QacB only
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transports monovalent cations. Sequence analysis and mu-
tagenesis revealed that the presence of an acidic residue in
TMS 10 (position 322 or 323) of these transporters is crucial
for the recognition of divalent cations (192). Altogether, these
results suggest that charge-charge interactions play an impor-
tant role in the recognition and export of lipophilic cations by
multidrug transporters.
Based on the observation that aromatic amino acid residues
in transmembrane regions of the human multidrug transporter
P-glycoprotein are highly conserved, Pawagi et al. (195) hy-
pothesized that the side chains of these residues can partici-
pate in the initial binding and subsequent transport of a variety
of ring-containing compounds. Indeed, Dougherty (47) indi-
cated that cation-p interactions between cations, such as quar-
ternary ammonium compounds, and aromatic side chains from
the amino acids Phe, Tyr, and Trp are important in a variety of
proteins that bind cationic substrates. The potential role of the
conserved aromatic residues Tyr59 and Trp62 in the staphylo-
coccal multidrug transporter Smr has been investigated by
site-directed mutagenesis (189). Substitutions at these posi-
tions abolished the multidrug efflux capacities of the protein,
indicating that these residues play a critical structural or func-
tional role. Mutations of residues Phe143, Val286, and Phe306 of
Bmr altered the sensitivity to reserpine and changed the sub-
strate specificity, indicating that these residues are likely in-
volved in substrate recognition (2, 111). Furthermore, muta-
tions of Phe, Trp, and Tyr residues in TMS 6, 11, and 12
drastically altered the drug resistance profile of P-glycoprotein
(82, 137). These results illustrate the importance of aromatic
and nonpolar amino acid residues in drug binding.
The three-dimensional structure of the multidrug-binding
domain of BmrR, the transcriptional activator of Bmr, sup-
ports a model in which a negatively charged amino acid residue
as well as aromatic and nonpolar residues is involved in drug
binding (284). The binding of TPP1 to Bmr induces the dis-
placement of a short amphipatic a-helix to allow the drug to
enter the drug-binding pocket. Inside the binding pocket,
TPP1 forms a number of van der Waals’ forces and stacking
interactions with the surrounding hydrophobic and aromatic
residues. The bottom of the binding pocket contains a buried
glutamate residue, which makes an electrostatic interaction
with the positively charged substrate (284). The substrate-bind-
ing site(s) of a multidrug transporter may have a similar orga-
nization. Most secondary multidrug transporters contain an
essential membrane-embedded negatively charged amino acid
residue. This residue could act like a magnet to attract posi-
tively charged substrates from the inner leaflet of the mem-
brane. The surrounding hydrophobic residues would impose
requirements on the size and shape of the substrate. In con-
trast to secondary multidrug transporters, the ABC multidrug
transporters LmrA, P-glycoprotein, and others do not contain
negatively charged residues in predicted TMS. It should also
be noted that the binding of neutral or negatively charged
substrates cannot be explained by the model described above.
There is increasing evidence for the presence of multiple
drug-binding sites in both secondary and ATP-dependent mul-
tidrug transporters, rather than a single binding site, as sug-
gested previously (126, 195). Tamai and Safa (245) indicated
for the first time that the human multidrug transporter P-
glycoprotein may contain at least two kinetically distinguish-
able drug-binding sites. Kinetic analysis of the drug-stimulated
ATPase activity of P-glycoprotein showed that cyclosporin A
competitively inhibits the verapamil-stimulated ATPase activ-
ity, whereas daunorubicin, gramicidin D, vinblastine, and col-
chicine give an allosteric inhibition. Interestingly, cooperative
stimulation of the verapamil-induced ATPase activity was
found with progesterone (131). Several other studies demon-
strated a similar complex effect of pairs of substrates or mod-
ulators on the drug-induced ATPase activity of P-glycoprotein
(30, 61, 153, 186). Noncompetitive inhibition of drug binding
(44, 56, 153, 264) and drug transport by P-glycoprotein (13,
196, 230, 238) further support a model with multiple cooper-
ating drug interaction sites.
Noncompetitive inhibition of rhodamine 6G transport by
drugs such as quinidine, puromycin, and colchicine also sug-
gested multiple cooperating drug interaction sites in the yeast
multidrug transporter Pdr5p (117). Van Veen et al. (257) dem-
onstrated that nicardipin interacts with the lactococcal multi-
drug transporter LmrA at a binding site distinct from but
allosterically linked to the vinca alkaloid-binding site. Compe-
tition studies showed that QacA-mediated transport of
ethidium is inhibited competitively by the monovalent cations
benzalkonium and tetraphenylarsonium and noncompetitively
by the divalent cations chlorhexidine and propamide. These
observations also suggest that the S. aureus multidrug trans-
porter QacA contains distinct binding sites for monovalent and
divalent cations (159). Furthermore, kinetic analysis of LmrP-
mediated Hoechst 33342 transport in inside-out membrane
vesicles revealed a competitive inhibition by verapamil and
quinine, a noncompetitive inhibition by nicardipin and vinblas-
tine, and a noncompetitive inhibition by TPP1, implying that
LmrP must contain at least two drug interaction sites (204).
These results indicate that the presence of two or more inter-
acting substrate-binding sites may be a general feature of mul-
tidrug efflux systems, including those of the SMR and RND
families.
MECHANISM OF TRANSPORT
The common ability of MDR substrates to intercalate in the
membrane led to the suggestion that multidrug transporters
transport their substrates from the lipid bilayer (88, 207, 252)
rather than from the cytoplasmic aqueous phase (7). Drug
recognition within the membrane is suggested by a number of
observations: (i) site-directed mutagenesis has identified spe-
cific residues implicated in substrate specificity, which are pre-
dominantly located within predicted TMS (2, 50, 65, 103, 184,
192), (ii) photoactive substrates label the human multidrug
transporter P-glycoprotein in or near transmembrane helices
(69, 207), and (iii) nonfluorescent acetoxymethyl esters of var-
ious fluorescent indicators, such as 29,79-bis-(2-carboxymethyl)-
5-(and 6)-carboxy-fluorescein (BCECF) and calcein, are ex-
truded from the membrane before they can be converted into
fluorescent carboxylates by nonspecific esterases in the cyto-
plasm (23, 89, 91).
The most convincing evidence for drug efflux from the mem-
brane to the aqueous phase, however, is provided by transport
studies using the fluorescent compounds TMA-DPH, Hoechst
33342, and 2-{4-[4-(dimethylamino)phenyl]-1,3-butadienyl}-
3-ethylbenzo-thiazolium perchlorate (LDS-751) which are
strongly fluorescent in a hydrophobic environment but essen-
tially nonfluorescent in an aqueous environment. Transport of
these compounds from the membrane to the aqueous phase
can be monitored as a decrease in fluorescence over time (22,
23, 180, 228, 229, 231). Shapiro et al. (229) demonstrated that
the initial rate of P-glycoprotein-mediated Hoechst 33342
transport is directly proportional to the amount of Hoechst
33342 in the membrane, demonstrating that P-glycoprotein
removes the drug from the lipid membrane. The mechanism of
transport of LmrA (23), LmrP (22), MexAB-OprM (180), and
QacA (159) was studied with TMA-DPH. TMA-DPH displays
a biphasic interaction with bacterial membranes; a fast parti-
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tioning of the probe in the outer leaflet of the phospholipid
bilayer, followed by a slower transbilayer movement of the
probe from the outer to the inner leaflet (23, 159). The initial
rate of TMA-DPH extrusion by the lactococcal multidrug
transporter LmrA increases with the concentration of TMA-
DPH in the inner leaflet, demonstrating that LmrA transports
drugs from the inner leaflet of the membrane (23). A similar
relationship between the initial rate of transport and the con-
centration of substrate in the inner leaflet of the membrane
was observed for LmrP (22) and P-glycoprotein (229, 231).
Also, the MDR transporters MexAB-OprM and QacA are
capable of strongly reducing the accumulation of TMA-DPH
in the inner leaflet of the bilayer (159, 180). Altogether, these
results demonstrate that the multidrug transporters of the
MFS, RND, and ABC families extrude toxic compounds from
the inner leaflet of the cytoplasmic membrane to the aqueous
extracellular medium (Fig. 8). Thus, despite differences in en-
ergy coupling, ATP- and PMF-dependent multidrug efflux
pumps display a general mechanism of transport for hydropho-
bic drugs.
Drug transport from the inner leaflet of the cytoplasmic
membrane to the extracellular aqueous medium requires a
high-affinity substrate-binding site that is accessible from the
inner leaflet of the phospholipid bilayer. This high-affinity site
is converted to a low-affinity outward-facing drug-binding site
at the expense of ATP hydrolysis or proton translocation. Re-
cently, drug transport cycles were described for the lactococcal
ABC-type multidrug transporter LmrA (258) and the E. coli
SMR-type multidrug transporter EmrE (165). Equilibrium
binding experiments, photoaffinity labeling studies, and drug
transport assays support the notion that homodimeric LmrA
mediates multidrug transport by an alternating two-site (two-
cylinder engine) mechanism. The transporter possesses two
drug-binding sites: a transport-competent site on the inner
membrane surface and a drug release site on the outer mem-
brane surface. The interconversion of these two sites is driven
by the hydrolysis of ATP. Indeed, a combination of total-
reflection Fourier transform infrared spectroscopy, 2H/H ex-
change, and fluorescence-quenching experiments indicated
that LmrA undergoes a secondary-structure change and passes
through three different conformational states during its drug
transport cycle (262). The mechanism proposed for LmrA may
also be relevant for P-glycoprotein and other ABC transporters
(258). For P-glycoprotein, evidence has been obtained which
supports a model of alternating catalytic sites (223). Both
NBDs are able to bind and hydrolyze ATP (92, 138). The two
nucleotide-binding sites interact strongly and cannot hydrolyze
Mg21-ATP simultaneously, suggesting that the two NBDs may
alternate in catalysis (93, 224, 253, 254).
EmrE, which contains a membrane-embedded glutamate
residue that is required for ligand binding and is proposed to
function as a homotrimer, binds 1 mol of TPP1 per ;3 mol of
ErmE. From the observation that both binding and release of
TPP1 from EmrE are strongly influenced by pH, Muth and
Schuldiner (165) proposed a mechanism of transport by EmrE.
As the substrate approaches the hydrophobic binding pocket,
two protons are released from the negatively charged gluta-
mate triplet. The positively charged substrate is bound through
electrostatic interactions with the negatively charged carboxy-
late groups of the glutamates. Following a currently unknown
conformational transition, the opening to the substrate-bind-
ing pocket becomes accessible to the external face of the mem-
brane while being closed off from the internal face. The sub-
sequent movement of two protons towards the binding pocket
catalyzes the release of the bound substrate. EmrE then un-
dergoes a conformational transition that converts the binding
pocket accessibility back to the original membrane face. As
most secondary multidrug transporters contain one or more
negatively charged amino acid residues in TMS, a similar
mechanism may be valid for other transporters. The available
techniques for purification and functional reconstitution of the
secondary multidrug transporters Smr, EmrE, NorA, LmrP,
and AcrB enable structural studies that can reveal conforma-
tional changes during the catalytic cycle.
FIG. 8. Extrusion of hydrophobic drugs by multidrug transporters. Drugs are expelled from the cytoplasmic leaflet of the membrane to the external medium.
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Bacterial multidrug efflux systems are a serious problem in
the pharmacological treatment of patients with infectious dis-
eases, since the substrate spectra of many multidrug transport-
ers include clinically relevant antibiotics. Multidrug transport-
ers are associated with both intrinsic and acquired resistance to
antibiotics. Disruption of the genes encoding AcrAB, MexAB-
OprM, HI0894/HI0895, NorA, and others causes increased
sensitivity to several antibiotics, demonstrating that these mul-
tidrug transporters are expressed in wild-type strains and con-
tribute to the intrinsic antibiotic resistance of E. coli, P. aerugi-
nosa, H. influenzae, and S. aureus, respectively (143, 199, 220,
271). In addition, it has been shown that the expression of
several genes encoding multidrug efflux pumps is inducible by
the drugs to which they offer protection and that the expression
of some multidrug transporters is modulated in response to
environmental conditions. Acquired MDR can arise via three
mechanisms: (i) amplification and mutations of genes encoding
multidrug transporters, which change the expression level
(174) or activity (113), (ii) mutations in specific or global reg-
ulatory genes which lead to the increased expression of multi-
drug transporters, exemplified by the mexR mutation in the
OCR1 strain of P. aeruginosa (201), and (iii) intercellular transfer
of resistance genes on transposons or plasmids, such as qacE
(108).
The clinical importance of multidrug transporters strongly
depends on the antibiotic spectrum to which they confer resis-
tance. The antibiotic resistance profiles of the multidrug trans-
porters known to date are summarized in Table 7. The data in
Table 7 clearly show that the drug resistance profiles of the
multidrug transporters vary strongly and family-specific pro-
files are not found. Resistance is observed against all important
classes of antibiotics. MexAB-OprM of P. aeruginosa and the
ABC-type multidrug transporter LmrA of L. lactis display very
broad antibiotic specificity, demonstrating that both secondary
and ATP-dependent multidrug transporters can seriously af-
fect the efficacy of many antibiotics. LmrA and the human
multidrug transporter P-glycoprotein are functionally inter-
changeable (257), suggesting that P-glycoprotein may also be
involved in export of antibiotics. Indeed, several Steptomyces
macrolide antibiotics have been reported to inhibit P-glyco
protein function (140). The plasmid-encoded multidrug trans-
porter HorA confers resistance to a smaller range of antibiotics
than the chromosomally encoded LmrA. However, since few
antibiotic resistance data are available for other plasmid-en-
coded multidrug transporters, such as QacA, QacB, and Smr,
it is not known whether a more restricted antibiotic resistance
profile is a general feature of plasmid-encoded multidrug
transporters. NorA and Bmr confer higher levels of resistance
to hydrophilic quinolones, such as norfloxacin and ciprofloxa-
cin, than to hydrophobic quinolones, such as sparfloxacin,
ofloxacin, and nalidixic acid (104, 171, 271, 278). Similarly,
norfloxacin transport by LfrA is inhibited by hydrophilic and
not by hydrophobic quinolones (134). This specificity for hy-
drophilic quinolones was also observed for PmrA and NorM
(63, 163). However, EmrB and VceB confer resistance only to
hydrophobic quinolones, whereas LmrA and the multidrug
transporters of the RND family transport both hydrophilic and
hydrophobic quinolones (37, 66, 135, 158, 200, 205). In addi-
tion to conferring resistance, the overexpression of multidrug
transporters can also cause increased drug sensitivity. The E.
coli multidrug transporter MdfA confers resistance to the ami-
noglycosides neomycin and kanamycin but causes hypersensi-
tivity to spectinomycin (19, 49). Overexpression of MexCD-OprJ
results in hypersusceptibility to gentamicin and carbenicillin but
not to ampicillin and penicillin (200, 240, 241). The mechanism of
this increased drug susceptibility remains to be studied.
PHYSIOLOGICAL FUNCTION
The efflux of a broad range of structurally unrelated toxic
compounds can be the primary physiological function of mul-
tidrug transporters or, alternatively, can be merely a fortuitous
side effect of the transport of an unidentified specific physio-
logical substrate (173). The latter role of MDRs would be
consistent with the observation that multidrug transporters
belong to four distinct families which are frequently more
homologous to substrate-specific transporters than to each
other (126). More convincing evidence for a role of multidrug
transporters in the efflux of a specific substrate comes from the
B. subtilis multidrug transporter Blt. Woolridge et al. (269)
demonstrated that overexpression of Blt results in an increased
efflux of spermidine in the medium. The blt gene is cotrans-
cribed with a downstream gene, btlD, which encodes a spermi-
dine acetyltransferase (4, 269). This genetic arrangement sug-
gests that the efflux of spermidine is the natural function of the
Blt transporter, whereas multiple drugs may be recognized
merely opportunistically. The ability of some MDR transport-
ers to mediate lipids or fluorescent lipid derivatives may indi-
cate that the physiological function of these multidrug trans-
porters involves phospholipid translocation or transport of
lipid-linked precursors of peptidoglycan (24, 90, 147, 254a,
280).
Alternatively, multidrug transporters may have evolved to
protect cells from diverse environmental toxins. Schinkel et al.
(222) demonstrated that disruption of the mouse mdr1a P-
glycoprotein gene leads to increased sensitivity to drugs such as
ivermectin and vinblastine. Similarly, increased antibiotic sus-
ceptibility was found in norA knockout mutants (94, 271). P-
glycoprotein and the E. coli multidrug transporter AcrAB are
induced in response to cellular damage (31) and stress condi-
tions (143), respectively. Furthermore, the substrate spectra of
several multidrug transporters include detergents (46, 203,
268), bile salts (80, 143, 249), organic solvents (266), and iono-
phores (54, 218, 233), suggesting that multidrug transporters
play a role in protection of the membrane integrity or energy
state of the cell.
CONCLUDING REMARKS
Multidrug transporters are a serious problem in the treat-
ment of patients with hospital- or community-acquired infec-
tious diseases, as they confer resistance to various of the anti-
biotics employed. A major force in the overexpression of
endogenous multidrug transporters and spread of plasmid-
encoded multidrug transporters is the huge consumption of
antibiotics in human therapy, animal husbandry, and agricul-
ture (12, 123). To restrain the evolution of antibiotic resis-
tance, several strategies have been proposed to reduce the
selective pressure of the presence of antibiotics (14, 123, 124,
267). The inappropriate use of antibiotics in household prod-
ucts, for the treatment of viral diseases, and as growth promot-
ers in farm animals should be reduced. In addition, the devel-
opment of new therapeutic agents is essential to fight the
increasing number of multidrug-resistant microorganisms. One
approach is to search for antibiotics with novel modes of ac-
tion, which will not face previously selected resistance deter-
minants. Alternatively, resistance-blocking agents can be iden-
tified and developed, allowing existing antibiotics to remain
effective (125, 149). Several inhibitors of the multidrug trans-
porters NorA and PmrA have been shown to increase the
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activity of fluoroquinolones against S. aureus and S. pneu-
moniae, respectively. Furthermore, these inhibitors dramati-
cally suppress the in vitro emergence of resistant strains (1,
151, 152). However, since the known inhibitors, such as reser-
pine, are toxic to humans, the development of nontoxic inhib-
itors is required. Detailed information about the structure-
function relationships that determine drug binding and
transport by multidrug transporters should provide us with a
rationale for these strategies.
Considerable progress has been made towards the identifi-
cation of amino acid residues implicated in drug binding. Mu-
tants of both ATP-dependent and secondary multidrug trans-
porters demonstrated that aromatic, nonpolar, and negatively
charged amino acid residues in predicted TMS are involved in
substrate binding by multidrug transporters. Increasing evi-
dence suggests the presence of multiple drug-binding sites, but
the exact number and their three-dimensional organization are
not known. Understanding the molecular mechanism of mul-
tidrug transport will ultimately require high-resolution struc-
tures of MDR proteins. As integral membrane proteins are
generally very difficult to crystalize, structures of MDR regu-
lator proteins which can bind a similar broad range of drugs
may provide useful information on the structure-function re-
lationships that dictate drug recognition. The low-resolution
structure of P-glycoprotein (211) and the high-resolution (2.7
Å) three-dimensional structure of the drug-binding region of
the regulator protein BmrR (284) are the first steps towards
resolving the mystery of the broad substrate specificity of mul-
tidrug transporters.
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